2018 AANS Annual Scientific Meeting-Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study

Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study

Back to course

Video Transcription

Video Summary

In this video presentation, Dr. Steinberg discusses the two-year safety and clinical outcomes of a Phase I-IIa study on chronic ischemic stroke patients who received modified bone marrow-derived mesenchymal stem cells. The study utilized allogeneic bone marrow cells that were cultured, transfected with a Notch gene plasmid, expanded, and then transplanted into the patients. The stem cells worked by producing trophic factors and enhancing native mechanisms of recovery. The study found that the treatment was safe and showed positive outcomes in terms of patient recovery. However, further research is needed to understand the mechanisms behind these results. A Phase II study with 156 patients has been initiated to further investigate the potential of stem cell therapy for stroke treatment.

Asset Caption

Gary K. Steinberg, MD, PhD, FAANS

Keywords

video presentation

Phase I-IIa study

chronic ischemic stroke

mesenchymal stem cells

safety and clinical outcomes